<DOC>
	<DOCNO>NCT01459575</DOCNO>
	<brief_summary>This open-label , Pilot study.The study hypothesis feasibility efficacy non-boosted ATV base HAART well first line treatment Chinese resource-limited setting .</brief_summary>
	<brief_title>Unboosted Atazanavir Initial ART Therapy China</brief_title>
	<detailed_description />
	<criteria>Signed write informed consent The subject establish HIV infection 6 month . Qualifying plasma HIV RNA ≥ 2,000 c/mL CD4 cell count within 100 350 cells/mm3 ≥16 year age Both female childbearing potential male must utilize effective barrier contraception contraception addition barrier method permit Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 4 week study manner risk pregnancy minimize . Patients unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . Presence newly diagnose HIVrelated opportunistic infection medical condition require acute therapy time enrollment . History hemophilia Proven suspect acute hepatitis 30 day prior study entry . Subjects chronic hepatitis eligible provide liver function enzyme &lt; 3 time upper limit normal . Presence cardiomyopathy . A history arrhythmia clinical symptom potentially related heart block second / third degree heart block . Inability tolerate oral medication Presence newly diagnose HIVrelated opportunistic infection medical condition require acute therapy time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>China</keyword>
</DOC>